7 September 2009 - Archimedes Pharma, the pan-European specialty pharmaceutical company, today announced that it has filed a New Drug Application (NDA) with the US Food & Drug Administration (FDA) for its lead development product, NasalFent, an innovative and highly differentiated fentanyl nasal spray for the rapid relief of breakthrough cancer pain.
The details can be read here.
No comments:
Post a Comment